经肝动脉化疗栓塞术联合索拉非尼治疗中晚期肝细胞癌研究进展

吴蕾; 王甦

doi:10.3969/j.issn.1001-5256.2018.04.037

经肝动脉化疗栓塞术联合索拉非尼治疗中晚期肝细胞癌研究进展

DOI: 10.3969/j.issn.1001-5256.2018.04.037

吴蕾,
王甦

扬州大学临床医学院附属苏北人民医院消化内科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1839
- HTML全文浏览量: 20
- PDF下载量: 381
- 被引次数: 0
出版历程
- 出版日期: 2018-04-20

Research advances in transarterial chemoembolization combined with sorafenib in treatment of advanced hepatocellular carcinoma

Wu Lei,
Wang Su

Department of Gastroenterology, Subei People′s Hospital Affiliated to Medical College of Yangzhou University

摘要

摘要: 经肝动脉化疗栓塞术(TACE)联合索拉非尼是目前治疗失去手术机会的中晚期肝细胞癌(HCC)最常用的策略,但具体治疗模式还未形成共识。分析了TACE联合索拉非尼治疗HCC的治疗模式及其有效性和安全性。认为不同的治疗模式均具有其利弊,还需要进行更多的临床研究,为中晚期肝癌患者的治疗提供一定参考。
- 癌,肝细胞 /
- 化学栓塞,治疗性 /
- 索拉非尼 /
- 综述
Abstract: At present, transarterial chemoembolization (TACE) combined with sorafenib is commonly used for patients with advanced hepatocellular carcinoma (HCC) who have lost the opportunity for surgery, and yet no consensus has been reached on the specific therapeutic paradigm.This article reviews the treatment modes of TACE combined with sorafenib and their effect and safety in the treatment of HCC.It is pointed out that these treatment modes have their own advantages and disadvantages and await further clinical studies, in order to provide a reference for the treatment of patients with advanced HCC.
- carcinoma, hepatocellular /
- chemoembolization, therapeutic /
- sorafenib /
- review

HTML全文

参考文献(47)

[1]ZHENG K, HE MG, WANG ZX.Therapeutic effect of transcatheter arterial chemoembolization combined with thalidomide or sorafenib in treatment of unresectable primary liver cancer:a comparative analysis[J].J Clin Hepatol, 2016, 32 (5) :899-903. (in Chinese) 郑康, 何盟国, 王智翔.经肝动脉化疗栓塞术联合沙利度胺或索拉非尼治疗不可切除原发性肝癌的效果比较[J].临床肝胆病杂志, 2016, 32 (5) :899-903.

[2]CUI HZ, DAI GH, SHI Y, et al.Sorafenib combined with TACE in advanced primary hepatocellular carcinoma[J].Hepatogastroenterology, 2013, 60 (122) :305-310.

[3]ZHANG MJ, LIU J, XIANG XX, et al.Research advances in sorafenib combined with orthotopic liver transplantation, radiofrequency ablation, and transar-terial chemoembolization in treatment of hepatocellular carcinoma[J].J Clin Hepatol, 2014, 30 (8) :829-832. (in Chinese) 张明娟, 刘佳, 向晓星, 等.索拉非尼联合肝移植、射频消融、肝动脉化疗栓塞治疗肝细胞癌的研究进展[J].临床肝胆病杂志, 2014, 30 (8) :829-832.

[4]NAKAMURA K, BEPPU T, HAYASHI H, et al.Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection[J].Int Surg, 2015, 100 (5) :908-914.

[5]WU FX, CHEN J, BAI T, et al.The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma[J].BMC Cancer, 2017, 17 (1) :645.

[6]LEE TY, LIN CC, CHEN CY, et al.Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma:a post hoc analysis of the START trial[J].Medicine, 2017, 96 (37) :e7655.

[7]YANG LY, QIN LX.Research hotspots and updates of diagnosis and treatment of hepatocellular carcinoma from 2017 annual meeting of the American Society of Clinical Oneology[J].Chin J Dig Surg, 2017, 16 (7) :674-679. (in Chinese) 杨璐宇, 钦伦秀.2017年美国临床肿瘤学会年会肝癌诊断与治疗研究热点和最新进展解析[J].中华消化外科杂志, 2017, 16 (7) :674-679.

[8]STREBEL BM, DUFOUR JF.Combined approach to hepatocellular carcinoma:a new treatment concept for nonresectable disease[J].Expert Rev Anticanc, 2008, 8 (11) :1743-1749.

[9]JEON SH, PARK KS, KIM YH, et al.Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma[J].Korean J Gastroenterol, 2007, 50 (3) :176-182.

[10]YE XP, PENG T, SHANG LM, et al.Clinical efficacy and toxicity of TACE combined with sorafenib in advanced hepatocellular carcinoma[J].Chin J Oncol Prev Treat, 2013, 5 (3) :242-245. (in Chinese) 叶新平, 彭涛, 尚丽明, 等.TACE联合索拉非尼治疗中晚期肝细胞性肝癌的临床研究[J].中国癌症防治杂志, 2013, 5 (3) :242-245.

[11]SHAO W, ZHANG F, NING C, et al.Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma[J].Oncol Lett, 2014, 8 (5) :2263-2266.

[12]LIU F, MENG Z, SHAO G, et al.Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population:subgroup analysis of the GIDEON study[J].Mol Biol Rep, 2017, 44 (1) :1-10.

[13]SANSONNO D, LAULETTA G, RUSSI S, et al.Transarterial chemoembolization plus sorafenib:a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma:a randomized clinical trial[J].Oncologist, 2012, 17 (3) :359-366

[14]SONG L, LYU S.Possibility of VEGF as a marker to evaluate effectiveness of intervention therapy to hepatorcellular carcinoma[J].J Dalian Med Univ, 2008, 30 (3) :232-235, 239. (in Chinese) 宋磊, 吕申.原发性肝癌TACE治疗前后血浆VEGF水平变化及其与疗效间相关性的研究[J].大连医科大学学报, 2008, 30 (3) :232-235, 239.

[15]KUDO M, IMANAKA K, CHIDA N, et al.Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J].Eur J Cancer, 2011, 47 (14) :2117-2127.

[16]SERGIO A, CRISTOFORI C, CARDIN R, et al.Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) :the role of angiogenesis and invasiveness[J].Am J Gastroenterol, 2008, 103 (4) :914-921.

[17]LI SY, WU S, CHEN TS, et al.Effect of portal venous perfusion cinobufacini injection combined with TACE in patients with intermediate hepatocellular carcinoma[J].Chin J Med Offic, 2017, 45 (9) :884-886. (in Chinese) 李淑英, 吴申, 陈挺松, 等.经导管肝动脉栓塞化疗联合华蟾素门静脉灌注治疗中期原发性肝癌疗效研究[J].临床军医杂志, 2017, 45 (9) :884-886.

[18]HU Z, WANG PE, QU HJ.The dynamic changes of serum VEGF, CTGF, HIF-1 and OPN levels in patients with advanced liver cancer treated with Sola Feeney combined with TACE[J].Chin J Biochem Pharm, 2017, 37 (4) :345-347. (in Chinese) 胡哲, 王培恩, 瞿海江.TACE联合索拉菲尼治疗晚期肝癌患者的疗效及对血清VEGF、CTGF、HIF-1α及OPN水平的影响[J].中国生化药物杂志, 2017, 37 (4) :345-347.

[19]LIU QS, SONG JL.Effect of sorafenib on levels of VEGF of patients with hepatocellular carcinoma after TACE[J].Chin J Cancer Prev Treat, 2012, 19 (12) :944-945. (in Chinese) 刘青山, 宋金龙.索拉非尼对原发性肝癌TACE后血管内皮生长因子水平影响的研究[J].中华肿瘤防治杂志, 2012, 19 (12) :944-945.

[20] HE XH, CHEN M, PENG JX, et al.Analysis of the dynamic changes of serum VEGF, CTGF, HIF-1 alpha and OPN levels in patients with advanced liver cancer treated with TACE combined with Sola Feeney[J].Med Equip, 2015, 28 (7) :81-82. (in Chinese) 贺旭辉, 陈勐, 彭晋修, 等.TACE联合索拉菲尼治疗晚期肝癌对患者血清VEGF、CTGF、HIF-1α和OPN水平的动态变化分析[J].医疗装备, 2015, 28 (7) :81-82.

[21]DING WJ, LI FP, GONG GW, et al.A comparative study on TACE combined with sorafenib versus TACE in the treatment of BCLC hepatocellular carcinoma[J].Anti-Tumor Pharm, 2015, 5 (3) :230-234. (in Chinese) 丁文金, 李飞平, 龚光文, 等.TACE联合索拉菲尼与TACE治疗巴塞罗那B期肝癌的临床对比研究[J].肿瘤药学, 2015, 5 (3) :230-234.

[22]GESCHWIND JF, KUDO M, MARRERO JA, et al.TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice:final analysis of GIDEON[J].Radiology, 2016, 279 (2) :630-640.

[23]SUN XY, LI CX, ZHANG K, et al.Sorafenib administration combined with TACE in treatment of unresectable hepatocellular carcinoma[J].Chin J Interv Imaging Ther, 2017, 14 (1) :3-7. (in Chinese) 孙向阳, 李彩霞, 张凯, 等.TACE联合索拉非尼治疗不可手术切除的肝癌[J].中国介入影像与治疗学, 2017, 14 (1) :3-7.

[24]GIUSCA SE, WIERZBICKI PM, AMALINEI C, et al.Comparative analysis of CD4 and CD8 lymphocytes-evidences for different distribution in primary and secondary liver tumors.[J].Folia Histochem Cyto, 2015, 53 (3) :272-281.

[25]YANG YJ, ZHANG HJ.Effects of sorafenib combined with transcatheter arterial chemoembolization on the prognosis and cellular immune function in patients with primary liver cancer[J/CD].Chin J Front Med Sci:Electronic Version, 2017, 9 (6) :121-125. (in Chinese) 杨瑜婧, 张慧娟.索拉非尼联合经导管动脉化疗栓塞对原发性肝癌患者预后及细胞免疫功能的影响[J/CD].中国医学前沿杂志:电子版, 2017, 9 (6) :121-125.

[26]OHMORI S, SHIRAKI K, SUGIMOTO K, et al.Expression of CD34-positive sinusoidal endothelial cells in patients with HBVassociated chronic liver diseases[J].Int J Mol Med, 2004, 14 (2) :179-184.

[27]ZHANG C, QI XS, BAI M, et al.Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma complicated by portal vein tumor thrombus[J].J Clin Hepatol, 2016, 32 (1) :84-87. (in Chinese) 张成, 祁兴顺, 柏明, 等.经肝动脉化疗栓塞术治疗肝细胞癌合并门静脉癌栓的预后影响因素分析[J].临床肝胆病杂志, 2016, 32 (1) :84-87.

[28]CHENG AL, KANG YK, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncol, 2009, 10 (1) :25-34.

[29]LENG JJ, XU YZ, DONG JH.Efficacy of transarterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis:a meta-analysis[J].Anz J Surg, 2014, 86 (10) :816-820.

[30]CHENG SQ.Treatment of hepatocellular carcinoma with portal vein tumor thrombus[M].Shanghai:Second Military Medical University Press, 2009:22-37. (in Chinese) 程树群.肝癌门静脉癌栓治疗[M].上海:第二军医大学出版社, 2009:22-37.

[31]LIU H, LI DT, YANG SR, et al.Efficacy of TACE in treatment of intraportal tumor thrombi with double helical CT[J].Bull Hunan Univ, 1999, 24 (1) :47-49. (in Chinese) 刘辉, 李德泰, 杨树仁, 等.运用螺旋CT观察TACE对门脉癌栓的作用[J].湖南医科大学学报, 1999, 24 (1) :47-49.

[32]ZHU K, CHEN J, LAI L, et al.Hepatocellular carcinoma with portal vein tumor thrombus:treatment with transarterial chemoembolization combined with sorafenib—a retrospective controlled study[J].Radiology, 2014, 272 (1) :284-293.

[33]HAO JL.Hepatic arterial chemoembolization in combination with sorafenib for primary liver cancer with portal vein tumor thrombus[D].Nanning:Guangxi Univ, 2015. (in Chinese) 郝金利.肝动脉插管灌注化疗栓塞术联合索拉非尼治疗原发性肝癌合并门静脉癌栓的疗效观察[D].南宁:广西医科大学, 2015.

[34]HA Y, LEE D, SHIM JH, et al.Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma[J].Oncotarget, 2016, 7 (45) :74303-74313.

[35]SHI J, LAI EC, LI N, et al.A new classification for hepatocellular carcinoma with portal vein tumor thrombus[J].J Hepato-Bil-Pan Sci, 2011, 18 (1) :74-80.

[36]OTSUKA T, EGUCHI Y, KAWAZOE S, et al.Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib[J].Hepatol Res, 2012, 42 (9) :879-886.

[37]ESTFAN B, BYRNE M, KIM R.Sorafenib in advanced hepatocellular carcinoma:hypertension as a potential surrogate marker for efficacy[J].Am J Clin Oncol, 2013, 36 (4) :319-324.

[38]KAMBA T, MCDONALD DM.Mechanisms of adverse effects of antiVEGF therapy for cancer[J].Brit J Cancer, 2007, 96 (12) :1788-1795.

[39]ERHARDT A, KOLLIGS FT, DOLLINGER MM, et al.TACE plus sorafenib for the treatment of hepatocellular carcinoma:final results of the multicenter SOCRATES trial[J].J Clin Oncol, 2011, 29 (Suppl 15) :4107.

[40]LEE TY, LIN CC, CHEN CY, et al.Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma:a post hoc analysis of the START trial[J].Medicine, 2017, 96 (37) :e7655.

[41]MARINELLI S, SALVATORE V, TOALDO MB, et al.Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma[J].BMC Cancer, 2014, 14:403.

[42]LI CX, SHI Y, GUO XC, et al.Mechanism of sorafenib resistance in hepatocellular carcinoma[J].Acad J Chinese PLA Postgrad Med Sch, 2017, 38 (4) :381-384. (in Chinese) 李晨曦, 石燕, 郭晓川, 等.晚期肝癌患者对索拉非尼耐药机制的研究进展[J].解放军医学院学报, 2017, 38 (4) :381-384.

[43]CHEN J, JIN R, ZHAO J, et al.Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.[J].Cancer Lett, 2015, 367 (1) :1-11.

[44]SHI YH, DING ZB, ZHOU J, et al.Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.[J].Autophagy, 2011, 7 (10) :1159-1172.

[45]GUO XC.Analysis of clinical pathological features and survival of advanced HCC patients treated with Sorafenib and study of the resistance mechanism induced by hypoxia[D].Beijing:Medical School of Chinese People's Liberation Army, 2016. (in Chinese) 郭晓川.甲苯磺酸索拉非尼治疗晚期原发性肝细胞癌患者的临床病理特征、生存预后分析及低氧诱导其耐药机制研究[D].北京:中国人民解放军医学院, 2016.

[46]CHEN YM, ZHANG BY, ZHANG JC, et al.Combination effect of SMMC-7221 hepatocarcinoma cells in vitro treated with all-trans retinoic acid and sorafenib[J].J Medical Forum, 2015, 36 (2) :44-49. (in Chinese) 陈彦明, 张炳勇, 张继承, 等.全反式维甲酸联合索拉菲尼对人SMMC-7721肝癌细胞株的作用[J].医药论坛杂志, 2015, 36 (2) :44-49.

[47]LI ML.Reversing effect of ECCG on Sorafenib resistance of human hepatocellular carcinoma cell lines[D].Yanji:Yanbian Univ, 2016. (in Chinese) 李明龙.EGCG逆转索拉菲尼耐药肝癌细胞的相关机制研究[D].延吉:延边大学, 2016.

施引文献

资源附件(0)

访问统计